Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Entyvio

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    - PMLiVE

    Abivax shares positive late-stage results for obefazimod in ulcerative colitis

    Inflammatory bowel disease affects nearly one in every 100 people in the US

    - PMLiVE

    Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

    The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

    - PMLiVE

    Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

    The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

    - PMLiVE

    Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

    The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

    - PMLiVE

    Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

    Around 800 people in the UK are diagnosed with late-stage disease every year

    - PMLiVE

    Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

    Up to 160,000 people in the US are affected by polycythaemia vera

    - PMLiVE

    Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

    Approximately three million people in Europe are affected by inflammatory bowel disease

    - PMLiVE

    Takeda’s mezagitamab shows promise in immune thrombocytopenia

    The rare immunoglobulin-mediated autoimmune disease affects four in every 100,000 people annually

    - PMLiVE

    Takeda’s Fruzaqla approved by EC to treat metastatic colorectal cancer in adults

    Approximately 538,000 new cases of colorectal cancer were diagnosed in Europe in 2022

    - PMLiVE

    Takeda shares long-term results for HyQvia in rare neurological disorder CIDP

    The therapy is the first and only facilitated subcutaneous immunoglobulin treatment for CIDP

    - PMLiVE

    Takeda shares late-stage results for investigational soticlestat in rare epileptic disorders

    Dravet syndrome and Lennox-Gastaut syndrome are drug-resistant to many anti-seizure medications

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links